RE:Filingsome of the milestones for the release of Tranches 2,3, and 4 are net revenue milestones, in addition FDA approval milestones:
quotes from the document:
US$20 million to be made available by no later than June 30, 2023 if the Corporation has filed with the FDA its sBLA for the EGRIFTA SV® human factor study and has had net revenues of at least US$75 million (Tranche 2);
US$15 million to be made available by no later than March 2024 if the Corporation has in the 12 month period preceding the funding of the tranche obtained approval from the FDA for its F8 formulation of tesamorelin and has had net revenues of at least US$90 million in the 12 month period preceding the funding of the tranche (Tranche 3);
Up to an additional US$25 million to be made available if the Corporation has had at least US$110 million in net revenues in the 12 month period preceding the funding of the - 2 - tranche and at least US$20 million in EBITDA (as defined in the Credit Agreement until December 2024) (Tranche 4);